skip to content
Detailed Quote
Questions on this company?
Become a Member
Company Profile
Interactive Chart
Key Ratios
Analyst Recommendations
5i Recent Questions

Q: If one believes in the potential importance of mRNA therapies to the future of human medicine in applications beyond COVID vaccines, which company would stand to benefit the most? Which are likely to benefit the most in the short term from COVID vaccines, or is this "baked in" for most already? Deduct points as needed and thank you for your excellent service.

Read Answer Asked by Jeff on March 23, 2021

Q: Haven’t seen a question since January. MDRA looks over sold and the stock has just issued a possible early technical buy signal using scholastics. More importantly this mRNA technology got another “shot in the arm” with the latest data indicting that they may work by STOPPING transmission not just mounting an immune response to decrease the course f the disease while you remain contagious. How well funded is MRNA. How is their free cash flow and their debt load. This technology keeps getting more and more exciting. Malaria, the common cold, HIV, etc!! And if is better maybe even influenza?
For the science geeks: Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening
Aaron J Tande, MD, Benjamin D Pollock, PhD, MSPH, Nilay D Shah, PhD, Gianrico Farrugia, MD, Abinash Virk, MD, Melanie Swift, MD, MPH, Laura Breeher, MD, MPH, Matthew Binnicker, PhD, Elie F Berbari, MD Author Notes
Clinical Infectious Diseases, ciab229,
Published: 10 March 2021

Read Answer Asked by Paul on March 15, 2021
Share Information
SEC Filings
News and Media